Pramipexole

Generic Name: Pramipexole

Brand Names: Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N_₃S

CAS Number: 104632-26-0

Unique Ingredient Identifier: 83619PEU5T

Background: Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...

Indication: This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .

Associated Conditions: Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)

Associated Therapies: -

Clinical Trials

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-11

Last Posted Date: 2014-09-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 497

Registration Number: NCT02236728

Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Bromocriptine and other dopamine agonists

First Posted Date: 2014-09-08

Last Posted Date: 2014-09-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 705

Registration Number: NCT02233023

Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2014-06-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 150

Registration Number: NCT02177357

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo pramipexole
Drug: Bromocriptine
Drug: Placebo bromocriptine

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 315

Registration Number: NCT02172573

Imaging Dopamine Release in Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Pramipexole

First Posted Date: 2014-01-10

Last Posted Date: 2019-11-01

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 52

Registration Number: NCT02033369

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome

Phase 4

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2014-01-01

Last Posted Date: 2017-01-24

Lead Sponsor: Mauro Manconi

Target Recruit Count: 20

Registration Number: NCT02025608

Locations: 🇨🇭
Department of Neurology, Inselspital, Bern, Switzerland
🇨🇭
Neurocenter of Southern Switzerland, Lugano, Ticino, Switzerland

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: pramipexole
Drug: Bromocriptine

First Posted Date: 2012-08-28

Last Posted Date: 2017-09-15

Lead Sponsor: Sandoz

Target Recruit Count: 121

Registration Number: NCT01673724

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 4 locations

Pramipexole as a Treatment for Cocaine Dependence

Phase 1

Completed

Conditions: Cocaine Abuse
Cocaine Addiction
Cocaine Dependence
Substance Abuse

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2012-07-27

Last Posted Date: 2014-07-22

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 10

Registration Number: NCT01651377

Locations: 🇺🇸
Michael E. DeBakey VA Medical Center, Houston, Texas, United States

The Effect of Pramipexole on Metabolic Network Activity Compared With Levodopa in Early Parkinson's Disease

Not Applicable

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Drug: Sinemet CR
Drug: pramipexole

First Posted Date: 2011-11-11

Last Posted Date: 2015-10-21

Lead Sponsor: Huashan Hospital

Target Recruit Count: 30

Registration Number: NCT01470859

Locations: 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor

Phase 3

Withdrawn

Conditions: Essential Tremor

Interventions: Drug: pramipexole
Drug: placebo

First Posted Date: 2011-09-27

Last Posted Date: 2017-05-08

Lead Sponsor: University of Pecs

Registration Number: NCT01441284

Locations: 🇭🇺
Department of Neurology, University of Pécs, Pécs, Baranya Megye, Hungary
🇭🇺
Kaposi Mór County Hospital, Kaposvár, Somogy Megye, Hungary

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy